Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D Investment by 9 Major Companies Increases 3.5% in First 6 Months
January 22, 2001
- SCRIP Tokyo Office Moves
January 22, 2001
- Daiichi Pure Chemicals Starts Contract SNP Analysis Services
January 22, 2001
- Merger with Mitsui Pharm Strengthens Schering Group's Product Line
January 22, 2001
- 15 Researchers Win AstraZeneca Asthma Research Award
January 22, 2001
- Cancer to Be Next 'Franchise' Area Following CNS, GI Fields: Mr Shinoda of Eisai
January 22, 2001
- New Kosei-Rodosho Inaugurated on Jan. 6
January 22, 2001
- Kyushu Univ. Opens Master's Course to Train Specialized Medical Professionals
January 22, 2001
- National Organization Proposed to Train CRCs: Kyoto Univ. Seminar
January 22, 2001
- Kosei-Rodosho Wants to Settle All Drug Price Issues in 2002 Reform
January 22, 2001
- Ain Pharmaciez to Become No. 1 Dispensing Pharmacy Operator: Report
January 22, 2001
- SBS, GSK Copromote Antidepressant
January 22, 2001
- Revised GPMSP to Be Enforced from October 1
January 22, 2001
- OTC NEWS IN BRIEF
January 22, 2001
- Santen Markets Betimol for Glaucoma in the US
January 22, 2001
- LDP Hashimoto Group Proposes Copayment of 10% or More for Elderly Healthcare
January 22, 2001
- DIAGNOSTIC NEWS IN BRIEF
January 22, 2001
- Life Science Units of Tomen, Nichimen to Merge into New Company
January 22, 2001
- CPAC Members Fail to Form Consensus on Production, Supply of Blood Preparations
January 22, 2001
- MEDICAL DEVICE NEWS IN BRIEF
January 22, 2001
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…